Mofezolac
Grundinformationen
- CAS
78967-07-4- Standard-SMILES
COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1- InChIKey
DJEIHHYCDCTAAH-UHFFFAOYSA-N- Summenformel
- C19H17NO5
- Durchschnittliche Molmasse
- 339,3 g/mol
- Monoisotopische Masse
- 339,11067264
Überblick
Mofezolac (TN) is a member of methoxybenzenes.
Namen und Bezeichner
- Bevorzugter Name
- Mofezolac
- IUPAC
- 2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid
- Englischer Name
- Mofezolac
- Summenformel
- C19H17NO5
- Molmasse
- 339.34
Namen und Synonyme
mofezolac78967-07-4MofezolacoMofezolacumDTXSID1046716RVJ0BV3H3YDTXCID9026716(3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid3,4-DMPIAAN-22 compound[3,4-bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid(3,4-di-(4-methoxyphenyl)-5-isoxazolyl)acetic acid
Weitere Namen anzeigen
Mofezolac, 10 mM in DMSO3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acidα-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid
RefChem:159308Disopain2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acidMofezolac [INN]N-222-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-Mofezolac (TN)
Datenbank-Bezeichner
- CAS
78967-07-4- PubChem CID
- 4237
- DTXSID
DTXSID1046716- ChEMBL
CHEMBL259972
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 3,1
- Polarare Oberfläche (TPSA)
- 81,8 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 25
- Formalladung
- 0
- Komplexität
- 430
Physikochemische Eigenschaften
- Schmelzpunkt
- 147.5 ℃ · 147.5℃
- Siedepunkt
- 527.2 · 527.2±50.0 °C(Predicted)
- Dichte
- 1.25 · 1.250±0.06 g/cm3(Predicted)
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- DMSO: soluble
- Aggregatzustand
- A solid
- pka
- 3.3 · pKa ~3.3(at 25℃)
- Farbe
- White to off-white
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- Toxizität
- LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh)
Chemie und Industrie
Pharmakologische Informationen
MeSH Pharmacological ClassificationCompounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
Anwendungen
BeschreibungMofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in Japan for the treatment of post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent suppression in various writhing models than agents such as ibuprofen, mefenamic acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. The ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of indomethacin and other agents.
Anbieter40 Anbieter
陕西缔都医药有限责任公司029-81124775 17791530730 · [email protected]
Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
杭州摩库生物医药科技有限公司
Zugehörige Reaktionen
3
Notizen zur Verbindung
Wird geladen…